(Q46795893)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18213730%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

title

Phase II study of gefitinib for the treatment of recurrent and metastatic nasopharyngeal carcinoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18213730%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18213730%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

author name string

Daniel T T Chua

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18213730%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Maria P Wong

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18213730%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Jonathan S T Sham

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18213730%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

John Nicholls

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18213730%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Gordon K H Au

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18213730%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

publication date

1 July 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18213730%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18213730%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

volume

30

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18213730%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18213730%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

page(s)

863-867

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18213730%20AND%20SRC:MED&resulttype=core&format=json

Epstein-Barr virus-encoded latent membrane protein 1 co-expresses with epidermal growth factor receptor in nasopharyngeal carcinoma

1 January 2020

cites work

1 reference

Prognostic value of epidermal growth factor receptor expression in patients with advanced stage nasopharyngeal carcinoma treated with induction chemotherapy and radiotherapy

21 January 2018

1 reference

Prognosticators determining survival subsequent to distant metastasis from nasopharyngeal carcinoma

21 January 2018

1 reference

7 January 2021

Long-term disease-free survivors in metastatic undifferentiated carcinoma of nasopharyngeal type

1 reference

7 January 2021

A phase II study of combination paclitaxel and carboplatin in advanced nasopharyngeal carcinoma

1 reference

7 January 2021

A phase II study of ifosfamide, 5-fluorouracil and leucovorin in patients with recurrent nasopharyngeal carcinoma previously treated with platinum chemotherapy

1 reference

7 January 2021

Combination gemcitabine and cisplatin chemotherapy for metastatic or recurrent nasopharyngeal carcinoma: report of a phase II study.

1 reference

7 January 2021

Significance of epidermal growth factor receptor and tumor associated tissue eosinophilia in the prognosis of patients with nasopharyngeal carcinoma

1 reference

7 January 2021

Expression of epidermal growth factor receptor in head and neck cancers correlates with clinical progression: a multicentre immunohistochemical study in the Asia-Pacific region

1 reference

7 January 2021

Prognostic significance of tumor angiogenesis, Ki 67, p53 oncoprotein, epidermal growth factor receptor and HER2 receptor protein expression in undifferentiated nasopharyngeal carcinoma--a prospective study.

1 reference

7 January 2021

Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck

1 reference

7 January 2021

Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck

1 reference

7 January 2021

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

1 reference

7 January 2021

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

1 reference

7 January 2021

Hormone replacement therapy and survival after colorectal cancer diagnosis.

1 reference

7 January 2021

Survival outcome of patients with nasopharyngeal carcinoma with first local failure: A study by the Hong Kong Nasopharyngeal Carcinoma Study Group

1 reference

7 January 2021

Lung metastasis alone in nasopharyngeal carcinoma: A relatively favorable prognostic group

1 reference

7 January 2021